Ixazomib for the treatment of multiple myeloma

Bibliography

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDS and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149–57
   PubMed Web of Science ®Google Scholar
• Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13–21
   PubMed Web of Science ®Google Scholar
• Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151–60
   PubMed Web of Science ®Google Scholar
• Orlowski M, Wilk S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 2000;383:1–16
   PubMed Web of Science ®Google Scholar
• Rechsteiner MC. Ubiquitin-mediated proteolysis: an ideal pathway for systems biology analysis. Adv Exp Med Biol 2004;547:49–59
   PubMed Web of Science ®Google Scholar
• Groll M, Heinemeyer W, Jager S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Nat Acad Sci 1999;96:10975–83
   Web of Science ®Google Scholar
• Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463–71
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Baldwin AS. NF-KB as a therapeutic target in cancer. Trend Mol Med 2002;8:385–9
   PubMed Web of Science ®Google Scholar
• Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104–12
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–47
   PubMed Web of Science ®Google Scholar
• Mitsiades NJ, Mitsiades CS, Poulaki V, et al. Biological sequelae of NFkB blockade in multiple myeloma: Therapeutic applications. Blood 2002;99:4079–86
   PubMed Web of Science ®Google Scholar
• Mitsiades NJ, Mitsiades CS, Richardson P, et al. The proteasome inhibitor PS-341 potentiates sensivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377–1280
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630–9
   PubMed Web of Science ®Google Scholar
• Hussain AR, Ahmed M, Ahmed SO, et al. Proteasome inhibitor MG-132 mediated expression of p27Kipl via S-phase kinase protein 2 degradation induces cell cycle couple apoptosis in primary effusion lymphoma cells. Leuk Lymphoma 2009;50:1204–13
   PubMed Web of Science ®Google Scholar
• Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Common Signal 2011;5:101–10
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184–91
   PubMed Web of Science ®Google Scholar
• Tamura D, Arao T, Tanaka K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010;101:1403–8
   PubMed Web of Science ®Google Scholar
• Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783–92
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DH, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma. Blood 2006;107:4907–16
   PubMed Web of Science ®Google Scholar
• Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008;9:944–57
   PubMed Web of Science ®Google Scholar
• Hertz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nar Rev Mol Cell Biol 2012;13:89–102
   PubMed Web of Science ®Google Scholar
• Monaco JJ. A Molecular Model of MHC class-I-restricted antigen processing. Immunol Today 1992;13:173–9
   PubMedGoogle Scholar
• Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 2012;49:258–62
   PubMed Web of Science ®Google Scholar
• Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des 2013;19:4140–51
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98
   PubMed Web of Science ®Google Scholar
• Teicher BA, Anderson KC. CCR20th anniversary commentary: in the beginning, there was PS341. Clin Cancer Res 2015;21:939–41
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–85
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679–86
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–17
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–72
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–901
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol 2015;96:1–9
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817–25
   PubMed Web of Science ®Google Scholar
• Stewart KA, Rajkumar VS, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–52
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results from the phase III study ENDEAVOR. J Clin Oncol 2015;33:8509
   Web of Science ®Google Scholar
• Ludwig H, Masszi T, Petrucci MT, et al. Carfilzomib vs low-dose corticosteroids and optional cyclophosphamide in patients with relapsed and refractory multiple myeloma. Ann Oncol 2014;25:abstract LBA28
   Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing of the investigational oral proteasome inhibitor ixaomib, in relapsed/refractory multiple myeloma. Blood 2014;124:1047–55
   PubMed Web of Science ®Google Scholar
• Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory myeloma patients. Blood 2014;124:1038–46
   PubMed Web of Science ®Google Scholar
• Kumar SK, Roy V, Reeder C, et al. Phase 2 trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib. Blood 2013;122:1944
   Google Scholar
• Berenson JR, Klein LM, Rifkin RM, et al. Results of the dose-escalation carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. J Clin Oncol 2014;32:8954
   Google Scholar
• Richardson PG, Hoffmeister CC, Rosenbaum CA, et al. Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma: final phase 1 results and phase 2 data. Blood 2013;122:535
   Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503–12
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801–9
   PubMed Web of Science ®Google Scholar
• Korde N, Zingone A, Kwok ML, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma patients. Blood 2013;122:538
   Google Scholar
• Hu B1, Chen Y, Usmani SZ, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS ONE 2013;8:e74191
   PubMed Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70:1970–80
   PubMed Web of Science ®Google Scholar
• Hollander MC, Zhan Q, Bae I, et al. Mammallian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem 1977;272:13731–3
   Web of Science ®Google Scholar
• Gupta N, Liu G, Berg D, et al. Clinical pharmacokinetics of intravenous and oral MLN9708, an investigational proteasome inhibitor: an analysis of data from four phase 1 monotherapy studies. Blood 2010;116:1813
   Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011;17:5311–21
   PubMed Web of Science ®Google Scholar
• Tian Z, Zhao J-J, Tai Y-T, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood 2012;120:3958–67
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res 2014;20:1542–54
   PubMed Web of Science ®Google Scholar
• Handa H, Suzuki K, Chou T, et al. Phase 1 study of the investigational proteasome inhibitor ixazomib alone or in combination with lenalidomide-dexamethasone in Japanese patients with relapsed and/or refractiory multiple myeloma. Blood 2014. 124:5752
   Google Scholar
• Gupta N, Zhao Y, Esseltine D-L, et al. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol 2015;79:789–800
   PubMed Web of Science ®Google Scholar
• San Miguel J, Hajek R, Spicka I, et al. Oral MLN9708, an investigational proteasome inhibitor, in combination with melphalan and prednisone in patients with previously untreated multiple myeloma: a phase I study [abstract 0293]. Haematologica 2012;97(Suppl 1):118–19
   Google Scholar
• Palumbo A, Gay F, Musto P, et al. Continous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints. J Clin Oncol 2014;32:8515
   Google Scholar
• Kumar S, Berdeja JG, Niesvizky R, et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma: phase 2 study results. Blood 2014;124:82
   Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–81
   PubMed Web of Science ®Google Scholar
• Shah JJ, Baladandayuthapani V, Weber DM, et al. Phase II study of the combination of MLN9708 with lenalidomide as maintenance therapy post autologous stem cell transplant in patients with multiple myeloma. Blood 2013;122:1983
   PubMed Web of Science ®Google Scholar
• A Phase 3 study comparing oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01564537?term=tourmaline+mm1&rank=1
   Google Scholar
• IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in adult patients with newly diagnosed multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01850524?term=tourmaline+mm2&rank=1
   Google Scholar
• A Study of Oral Ixazomib Citrate (MLN9708) maintenance therapy in patients with multiple myeloma following autologous stem cell transplantor following induction not including ASCT. Available from: https://clinicaltrials.gov/ct2/show/NCT02181413?term=tourmaline&rank=1
   Google Scholar
• Smith DC, Kalebic T, Infante JR, et al. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs 2015;33:652–63
   PubMed Web of Science ®Google Scholar
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis. Available from: https://clinicaltrials.gov/ct2/show/NCT02176486?term=ixazomib&rank=20
   Google Scholar